Supernus Pharmaceuticals’ (SUPN) “Buy” Rating Reaffirmed at B. Riley

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reaffirmed by investment analysts at B. Riley in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They presently have a $54.00 price objective on the specialty pharmaceutical company’s stock. B. Riley’s target price points to a potential upside of 15.14% from the company’s current price.

Other analysts have also issued reports about the stock. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. FBR & Co started coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. Cantor Fitzgerald restated a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. Jefferies Group reiterated a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Stifel Nicolaus upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Tuesday, November 7th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $49.90.

Supernus Pharmaceuticals (SUPN) traded up $3.35 during mid-day trading on Thursday, hitting $46.90. 1,230,000 shares of the company were exchanged, compared to its average volume of 557,137. Supernus Pharmaceuticals has a 12-month low of $23.10 and a 12-month high of $50.04. The stock has a market capitalization of $2,400.00, a price-to-earnings ratio of 42.64 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The firm’s revenue was up 41.5% compared to the same quarter last year. equities analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current year.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold 145,750 shares of company stock worth $6,173,173 over the last quarter. 6.70% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after acquiring an additional 31,331 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after acquiring an additional 984,200 shares during the period. State Street Corp boosted its holdings in shares of Supernus Pharmaceuticals by 3.1% in the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after acquiring an additional 42,165 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 2.0% in the fourth quarter. Acadian Asset Management LLC now owns 1,280,179 shares of the specialty pharmaceutical company’s stock valued at $51,013,000 after acquiring an additional 24,491 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Supernus Pharmaceuticals by 10.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after acquiring an additional 122,042 shares during the period. 98.22% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals’ (SUPN) “Buy” Rating Reaffirmed at B. Riley” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/21/supernus-pharmaceuticals-supn-buy-rating-reaffirmed-at-b-riley.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply